Breaking News, Collaborations & Alliances

Epizyme Earns Milestone Payment from GSK

Third Epizyme-discovered product candidate advances into clinical development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of patient dosing in a Phase 1 clinical trial of GSK3326595 (formerly EPZ015938), a first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor discovered by Epizyme and licensed to GSK. PRMT5 is a protein methyltransferase that is associated with a number of human cancers. “Ep...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters